MedTrace Logo

Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient

NCT04654195 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-12-04

No results posted yet for this study

Summary

polymorphisms of drug transporter genes may influence of Doxorubicin-Cyclophosphamide toxicity in breast cancer patients.

the investigators want to

evaluate the association between associations between genetic polymorphisms of ABCB1,SLC22A16 Genes and Toxicity of Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients treated by Doxorubicin-Cyclophosphamide regimen therapy

Conditions

  • Breast Cancer Patients

Interventions

GENETIC

polymorphism analysis

DNA will be purified from whole blood samples by commercial DNA isolation kits. Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR.

DRUG

Doxorubicin-Cyclophosphamide regimen

Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.

Sponsors & Collaborators

  • Al-Azhar University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Hoda salem, Ass.prof · Faculty of pharmacy Al-Azhar University for Girls

  • Wael helmy, Ass.prof · Faculty of medicine Al-Azhar University for Boys

  • Amira bisheer, PhD · faculty of pharmacy ,Damanhour University

  • sanaa mohsen, B.pharm · faculty of pharmacy,Al-Azhar University

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-02-01
Completion
2021-02-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04654195 on ClinicalTrials.gov